Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Limited today announced that the companies have entered into an exclusive…
Shanghai-based LaNova Medicines has been acquired by fellow Chinese biotech Sino Biopharmaceutical in a deal worth up to $951 million. In a Tuesday regulatory…
Sino Biopharmaceutical is taking full control of LaNova Medicines, agreeing to pay up to $951 million to acquire the approximately 95% of the Chinese biotech…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sino Biopharm agreed to acquire the ~95% of LaNova Medicines it didn't already own for up to $951M (net cash outlay ~$500M). Adds eight clinical-stage oncology assets including LM-299 (Merck-licensed PD-1/VEGF bispecific) and three ADCs, plus ~20 preclinical programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sino Biopharmaceutical Ltd. / LaNova Medicines Ltd. (this deal) | 2025 | $951M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2025 deals · Oncology deals